See more : Berry Global Group, Inc. (BERY) Income Statement Analysis – Financial Results
Complete financial analysis of Soligenix, Inc. (SNGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Soligenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Japan Craft Holdings Co., Ltd. (7135.T) Income Statement Analysis – Financial Results
- gumi Inc. (3903.T) Income Statement Analysis – Financial Results
- Vesync Co., Ltd (2148.HK) Income Statement Analysis – Financial Results
- VusionGroup (0OA4.L) Income Statement Analysis – Financial Results
- Titan NRG Inc. (TTNN) Income Statement Analysis – Financial Results
Soligenix, Inc. (SNGX)
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 839.36K | 948.91K | 824.27K | 2.36M | 4.63M | 5.24M | 5.43M | 10.45M | 8.77M | 7.04M | 3.22M | 3.14M | 7.66M | 1.95M | 2.82M | 2.31M | 1.26M | 2.31M | 3.08M | 997.48K | 83.82K | 0.00 | 0.00 | 0.00 | 1.00 | 200.00K | 100.00K | 0.00 |
| Cost of Revenue | 742.05K | 550.82K | 728.64K | 1.82M | 3.57M | 4.60M | 4.31M | 8.43M | 6.88M | 5.31M | 2.54M | 2.59M | 2.11M | 1.64M | 1.48M | 1.89M | 943.39K | 1.97M | 2.07M | 936.64K | 76.20K | 0.00 | 0.00 | 0.00 | -1.41M | -1.70M | -500.00K | 0.00 |
| Gross Profit | 97.31K | 398.09K | 95.63K | 538.50K | 1.06M | 643.73K | 1.12M | 2.02M | 1.89M | 1.73M | 679.87K | 551.55K | 5.55M | 309.23K | 1.33M | 423.83K | 314.63K | 347.95K | 1.01M | 60.85K | 7.62K | 0.00 | 0.00 | 0.00 | 1.41M | 1.90M | 600.00K | 0.00 |
| Gross Profit Ratio | 11.59% | 41.95% | 11.60% | 22.82% | 22.95% | 12.28% | 20.66% | 19.29% | 21.51% | 24.55% | 21.09% | 17.54% | 72.49% | 15.88% | 47.31% | 18.35% | 25.01% | 15.04% | 32.80% | 6.10% | 9.09% | 0.00% | 0.00% | 0.00% | 140,775,100.00% | 950.00% | 600.00% | 0.00% |
| Research & Development | 3.31M | 7.94M | 8.39M | 15.15M | 8.12M | 6.75M | 5.51M | 4.30M | 5.40M | 5.09M | 5.07M | 2.61M | 6.27M | 5.68M | 4.52M | 1.73M | 3.10M | 4.62M | 3.68M | 3.66M | 2.73M | 2.94M | 2.47M | 956.74K | 2.03M | 3.10M | 1.80M | 906.46K |
| General & Administrative | 4.48M | 6.69M | 4.85M | 3.98M | 3.48M | 2.95M | 3.21M | 3.43M | 3.60M | 3.40M | 2.77M | 2.56M | 0.00 | 2.50M | 2.86M | 2.15M | 0.00 | 0.00 | 0.00 | 0.00 | 2.51M | 1.97M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 68.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.48M | 6.69M | 4.85M | 3.98M | 3.48M | 2.95M | 3.21M | 3.43M | 3.60M | 3.40M | 2.77M | 2.63M | 2.24M | 2.50M | 2.86M | 2.15M | 3.54M | 3.11M | 2.16M | 2.32M | 2.51M | 2.99M | 1.97M | 2.10M | 3.05M | 3.50M | 1.50M | 317.24K |
| Other Expenses | 0.00 | -132.87K | -174.77K | -95.36K | -433.59K | 0.00 | 0.00 | 3.43M | 3.60M | 3.40M | 2.77M | 2.63M | 2.24M | 0.00 | 0.00 | 0.00 | 3.54M | 3.93M | 2.16M | 2.32M | 2.51M | 2.99M | 12.15M | 2.10M | 4.45M | 5.20M | 2.00M | 0.00 |
| Operating Expenses | 7.80M | 14.50M | 13.06M | 19.03M | 11.17M | 9.70M | 8.72M | 7.72M | 9.00M | 8.49M | 7.84M | 5.24M | 8.51M | 8.19M | 7.38M | 3.88M | 6.64M | 8.55M | 5.84M | 5.98M | 5.23M | 5.93M | 14.63M | 3.06M | 6.48M | 8.30M | 3.80M | 1.26M |
| Cost & Expenses | 8.54M | 15.05M | 13.79M | 20.85M | 14.74M | 14.30M | 13.03M | 16.16M | 15.88M | 13.80M | 10.38M | 7.84M | 10.62M | 9.83M | 8.87M | 5.77M | 7.59M | 10.51M | 7.91M | 6.91M | 5.31M | 5.93M | 14.63M | 3.06M | 5.08M | 6.60M | 3.30M | 1.26M |
| Interest Income | 0.00 | 822.61K | 904.50K | 10.88K | 148.97K | 159.01K | 29.91K | 0.00 | 0.00 | 1.31K | 1.96K | 6.20K | 7.44K | 12.07K | 21.92K | 37.07K | 164.85K | 41.51K | 114.79K | 66.54K | 28.71K | 105.68K | 424.03K | 747.07K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 49.13K | 822.61K | 862.58K | 10.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 742.00 | 2.68K | 3.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -35.84K | -35.84K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.55K | 137.28K | 150.45K | 193.04K | 177.56K | 44.06K | 68.56K | 89.93K | 247.46K | 245.79K | 230.07K | 230.63K | 226.03K | 185.70K | 175.60K | 149.18K | 119.57K | 137.04K | 194.28K | 302.45K | 226.14K | 345.50K | 188.53K | 156.86K | 1.41M | 1.70M | 500.00K | 204.46K |
| EBITDA | -7.85M | -14.11M | -12.23M | -18.23M | -9.36M | -9.01M | -7.53M | -5.62M | -6.86M | -6.52M | -6.93M | -4.45M | -2.73M | -7.45M | -5.86M | -3.31M | -6.21M | -8.02M | -4.64M | -5.61M | -5.00M | -6.45M | -3.86M | -2.90M | -3.67M | -4.80M | -2.70M | -1.06M |
| EBITDA Ratio | -935.58% | -1,483.34% | -1,565.17% | -781.06% | -216.96% | -171.99% | -138.52% | -72.27% | -64.56% | -84.51% | -101.47% | -141.83% | -35.58% | -394.36% | -208.57% | -143.13% | -493.33% | -313.28% | -150.88% | -562.94% | -5,934.78% | 0.00% | 0.00% | 0.00% | -80,576,000.00% | 5,250.00% | -2,900.00% | 0.00% |
| Operating Income | -7.70M | -14.11M | -12.97M | -18.49M | -10.11M | -9.06M | -7.59M | -5.71M | -7.11M | -10.76M | -7.16M | -4.69M | -2.96M | -7.88M | -6.05M | -3.46M | -6.33M | -8.20M | -4.84M | -5.92M | -5.23M | -5.93M | -14.63M | -3.06M | -5.08M | -6.40M | -3.20M | -1.26M |
| Operating Income Ratio | -917.12% | -1,486.55% | -1,573.05% | -783.71% | -218.31% | -172.83% | -139.79% | -54.64% | -81.09% | -152.79% | -221.97% | -149.16% | -38.63% | -404.51% | -214.89% | -149.59% | -502.94% | -354.50% | -157.20% | -593.21% | -6,236.06% | 0.00% | 0.00% | 0.00% | -507,562,800.00% | -3,200.00% | -3,200.00% | 0.00% |
| Total Other Income/Expenses | -210.59K | -714.37K | -449.60K | 61.09K | 574.75K | 159.01K | 29.91K | 1.93M | -1.21M | 3.44M | -3.65M | 6.20K | 7.44K | 246.03K | 16.84K | 33.80K | 162.44K | 36.20K | 114.79K | 45.54K | -61.65K | -5.92K | -5.92K | -2.43M | -2.86M | -15.20M | 200.00K | 74.85K |
| Income Before Tax | -7.91M | -14.95M | -13.42M | -18.53M | -9.97M | -8.90M | -7.56M | -3.78M | -8.32M | -7.32M | -10.81M | -4.68M | -2.95M | -7.63M | -6.05M | 0.00 | -6.33M | -9.02M | 0.00 | -5.92M | -5.29M | -14.63M | -14.63M | -5.49M | -7.94M | -21.60M | -3.00M | -1.19M |
| Income Before Tax Ratio | -942.21% | -1,575.84% | -1,627.59% | -785.16% | -215.26% | -169.80% | -139.23% | -36.13% | -94.89% | -103.99% | -335.26% | -148.97% | -38.53% | -391.88% | -214.97% | 0.00% | -503.05% | -389.79% | 0.00% | -593.15% | -6,309.62% | 0.00% | 0.00% | 0.00% | -793,774,600.00% | -10,800.00% | -3,000.00% | 0.00% |
| Income Tax Expense | -1.77M | -1.15M | -864.74K | -836.89K | -610.68K | 159.01K | -416.81K | -530.14K | -488.93K | -616.87K | -750.36K | -521.46K | -574.16K | -245.81K | -16.84K | -33.80K | -162.44K | -36.20K | -114.79K | -45.54K | 61.65K | -965.43K | 5.92K | 1.74M | 2.43M | 15.40M | 0.00 | 0.00 |
| Net Income | -6.14M | -13.80M | -12.55M | -17.69M | -9.36M | -8.90M | -7.15M | -3.25M | -7.83M | -6.71M | -10.06M | -4.16M | -2.38M | -7.39M | -6.03M | -3.42M | -6.16M | -8.16M | -4.72M | -5.87M | -5.29M | -4.97M | -14.63M | -4.80M | -7.50M | -21.80M | -3.20M | -1.19M |
| Net Income Ratio | -731.60% | -1,454.12% | -1,522.68% | -749.69% | -202.07% | -169.80% | -131.56% | -31.06% | -89.31% | -95.23% | -311.99% | -132.39% | -31.04% | -379.26% | -214.29% | -148.12% | -490.03% | -352.93% | -153.47% | -588.64% | -6,309.62% | 0.00% | 0.00% | 0.00% | -750,101,900.00% | -10,900.00% | -3,200.00% | 0.00% |
| EPS | -12.66 | -76.96 | -75.06 | -154.45 | -115.88 | -162.09 | -279.17 | -223.73 | -721.04 | 0.00 | 0.00 | -56.07 | -32.56 | -109.48 | -108.07 | -100.77 | -203.93 | -384.10 | -284.78 | -433.58 | -543.70 | -662.23 | -3.26K | -1.18K | -2.09K | -6.57K | -3.06K | -703.37 |
| EPS Diluted | -12.66 | -76.89 | -75.06 | -154.45 | -115.88 | -162.09 | -279.17 | -320.56 | -721.04 | 0.00 | 0.00 | -56.07 | -32.56 | -109.48 | -108.07 | -100.77 | -203.93 | -384.10 | -284.78 | -433.58 | -543.70 | -662.23 | -3.26K | -1.18K | -2.09K | -6.57K | -3.06K | -703.37 |
| Weighted Avg Shares Out | 484.88K | 179.29K | 167.22K | 114.53K | 80.74K | 54.91K | 25.60K | 10.12K | 10.86K | 0.00 | 0.00 | 74.24K | 73.05K | 67.47K | 55.84K | 33.96K | 30.23K | 21.25K | 16.58K | 13.54K | 9.73K | 7.50K | 4.48K | 4.06K | 3.59K | 3.32K | 1.05K | 1.69K |
| Weighted Avg Shares Out (Dil) | 484.88K | 179.46K | 167.22K | 114.53K | 80.74K | 54.91K | 25.60K | 14.93K | 10.86K | 0.00 | 0.00 | 74.24K | 73.05K | 67.47K | 55.84K | 33.96K | 30.23K | 21.25K | 16.58K | 13.54K | 9.73K | 7.50K | 4.48K | 4.06K | 3.59K | 3.32K | 1.05K | 1.69K |
SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 13, 2023 / RedChip Companies will air interviews with SPI Energy Co., Ltd., (NASDAQ:SPI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday,...
Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (Nasdaq:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) on The RedChip Small Stocks Big Money Show®, a sponsored program on Bloomberg TV,...
Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
Vaccines stable for at least two years when stored at 40 degrees Celsius / 104 degrees Fahrenheit Only subunit (protein) vaccine platform shown to protect against potentially lethal Ebola and Marburg viruses No cold chain storage and transport required as...
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
PRINCETON, N.J. , Sept. 22, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that...
Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
PRINCETON, N.J. , August 21, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments...
BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / August 11, 2023 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, August 12, at 7 p.m....
HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , Aug. 10, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where...
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis
Clear biological signal demonstrated; additional patients to be enrolled PRINCETON, N.J. , July 11, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where...
Soligenix shares spike after T-cell lymphoma candidate HyBryte aces compatibility study results
Soligenix (NASDAQ:SNGX) shares more than doubled on Thursday after the biopharmaceutical company announced positive results from a compatibility study of its investigational therapeutic HyBryte in cutaneous T-cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device. The company...
Soligenix stock slumps as cancer drug application is knocked back
Soligenix (NASDAQ:SNGX) slumped in Tuesday's early deals after revealing its cancer drug has been knocked back by the US Food and Drug Administration. The company, in a statement, told investors that it has received a Refusal to File (RTF) letter...
Source: https://incomestatements.info
Category: Stock Reports